Clinical Trial: Electrophysiologic Measures of Treatment Response in Alzheimer Disease


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

This study is currently recruiting patients.

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs

Purpose

The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.

Condition	Treatment or Intervention	Phase
Alzheimer Disease	Drug: Aricept Drug: Exelon Drug: Nicoderm Patch	Phase IV

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Crossover Assignment, Efficacy Study

Official Title: Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease

Further Study Details:

Study start: October 1998; Study completion: September 2001

Eligibility

Ages Eligible for Study: 55 Years - 85 Years, Genders Eligible for Study: Both

Accepts Healthy Volunteers

Criteria

Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state exam scores between 15-27), and normal controls (age generally between 60-85). Subjects must either be planning to start daily cholinesterase therapy (e.g. Aricept, Exelon) or willing to try a transdermal nicotine patch for two 8 hour periods.

Location and Contact Information

California
Department of Veterans Affairs, San Diego, California, 92161, United States; Recruiting

Shaunna K. Morris, Ph.D. 858-552-8585 Ext. 2895 skmorris@ucsd.edu
John M. Olichney, Principal Investigator

Study chairs or principal investigators

Vincente Iragui, M.D., Ph.D
Shuanna Morris, Ph.D.

More Information

Study ID Numbers: AGCG-004-98S
Record last reviewed: June 2001
Record first received: July 3, 2001
ClinicalTrials.gov Identifier: NCT00018278
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-09

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services